Asensus Surgical

Asensus Surgical EBITDA per Employee

Delisted

The EBITDA per Employee of Asensus Surgical (ASXC) as of Oct 22, 2026 is -606,851.56 USD. In the previous year, EBITDA per Employee was -531,007.81 USD — a change of 14.28% (lower).

EBITDA per Employee

-606,851.56USD

YoY

14.28%

Last updated:

EBITDA per Employee of Asensus Surgical is 2023 -606,851.56 USD. EBITDA per Employee of Asensus Surgical was 2022 -531,007.81 USD. It decreases by 14.28% lower compared to the previous year.

The Asensus Surgical EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2016
-911,554.69 USD
Jan 1, 2017
-422,398.44 USD
Jan 1, 2018
-402,156.25 USD
Jan 1, 2019
-1.13 M USD
Jan 1, 2020
-387,414.06 USD
Jan 1, 2021
-416,945.31 USD
Jan 1, 2022
-531,007.81 USD
Jan 1, 2023
-606,851.56 USD
The Asensus Surgical EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-606,851.56USD+14.28%
-531,007.81USD+27.36%
-416,945.31USD+7.62%
-387,414.06USD-65.63%
-1.13 MUSD+180.28%
-402,156.25USD-4.79%
-422,398.44USD-53.66%
-911,554.69USD+164.09%
-345,164.06USD+22.35%
-282,101.56USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Asensus Surgical Stock analysis

What does Asensus Surgical do? Asensus Surgical Inc is a medical technology company based in Research Triangle Park, North Carolina, USA. It was founded in 1995 by Joe Mussallem, who still serves as President and CEO today. Formerly known as "TransEnterix," the company changed its name to Asensus Surgical Inc in 2021 to reflect its commitment to advanced, data-driven surgery. Asensus Surgical Inc aims to revolutionize the way surgical procedures are performed by utilizing robotic technology and offering a wide range of products and services. The company's business model is based on transferring skills typically held by surgeons to robots, with a focus on precision in surgeries. Through the use of machine learning and computer vision, Asensus Surgical Inc allows surgeons to monitor their own movements in real-time on robotic arms in the operating room, leading to significantly more precise work. The company's main division is the Senhance® Surgical System platform. The system consists of three components: the artificial intelligence technology of the Intelligent Surgical Units (ISU), touchscreen consoles, and a further sterilization cabinet. During surgical procedures, the Intelligent Surgical Units process real-time data, enabling improved decision-making during the operation. The touchscreen consoles serve as the user interface, allowing surgeons to monitor and control the operation in real-time on a screen. The sterilization cabinet ensures that the system is sterilized between procedures. In addition to the Senhance® Surgical System platform, Asensus Surgical Inc also offers other innovative products such as disposable instruments. This includes "3-mm instruments," special miniature instruments that can be used through very small incisions in the patient's body. These minimize scarring and enable faster recovery. Another product offered by Asensus Surgical Inc is the AI Camera Assistant, which is based on artificial intelligence (AI). This is a computer software that supports surgeons by analyzing real-time images and enabling monitoring and analysis during the procedure. Combined with the Senhance® Surgical System, the AI Camera Assistant allows for more precise and safer work. Asensus Surgical Inc has achieved several significant milestones in its history. One of these milestones is the FDA approval of the Senhance® Surgical System platform in 2017. Furthermore, in 2020, the company entered into an agreement with Johnson & Johnson to advance the marketing of products. Overall, Asensus Surgical Inc is an emerging company in the highly innovative field of robotics in surgery. With its advanced products and focus on precise, safe, and straightforward surgery, the company will continue to play an important role in the healthcare industry, saving and improving lives. Asensus Surgical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Asensus Surgical stock

EBITDA per Employee of Asensus Surgical is -606,851.56 USD in 2023.

EBITDA per Employee of Asensus Surgical changed from -531,007.81 USD to -606,851.56 USD, representing a 14.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Asensus Surgical since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Asensus Surgical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Asensus Surgical

All Key Metrics — Asensus Surgical